This study aims to evaluate the combination effects of cisplatin, gemcitabine, and the APC/C inhibitor proTAME on cell migration as well as MMP2 and MMP9 expression in bladder cancer (RT4 cells) and normal epithelial cells (ARPE-19) as the control. Here, MMP2 is linked to urinary bladder cancer.